Name:
REDUCE IT EPA: A New Era of CV Therapies
Description:
REDUCE IT EPA: A New Era of CV Therapies
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/ae9bc733-a716-4ddc-88e8-1c5b944cc501/thumbnails/ae9bc733-a716-4ddc-88e8-1c5b944cc501.jpeg?sv=2019-02-02&sr=c&sig=nJhzqgqzN9uvVY8XUBqooHQidvGP3VtmKWzMrYGdZio%3D&st=2024-12-21T14%3A46%3A23Z&se=2024-12-21T18%3A51%3A23Z&sp=r
Duration:
T00H03M47S
Embed URL:
https://stream.cadmore.media/player/ae9bc733-a716-4ddc-88e8-1c5b944cc501
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/ae9bc733-a716-4ddc-88e8-1c5b944cc501/18777433.mp3?sv=2019-02-02&sr=c&sig=jK50afb63sd2PXwqwZywDI1ZKlR7lJhbMVU3nJGLXA4%3D&st=2024-12-21T14%3A46%3A23Z&se=2024-12-21T16%3A51%3A23Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst, the Heart Board Review, and other online resources available only through accesscardiology.com. [ Music ] What do we really know about omega-3 now? Previously, studies were not very conclusive of the cardiovascular benefits. And that may have been related to the fact that the components of omega-3 were not evaluated independently. [ Music ] >> Hi, Dr. Bernie here, and welcome again to Practice Impact Extra.
Omega-3. What about omega-3 and cardiac events? This has been evaluated over the past several years. And in particular, attention is now focused on EPA, the EPA fatty acid. And what kind of outcomes are we seeing with the pure prescriptive EPA? And so really, what do we know now? Well, previously -- we previously published in the New England Journal of Medicine in 2019 was the REDUCE-IT trial.
This was a global study that included 8,179 patients who had elevated cardiovascular risk already taking statins, but also have an elevated triglyceride levels between 135 and 499 milligrams per deciliter. Well, the 4.9-year outcome of this trial found that Icosapent, 4 grams daily, compared with placebo led to a reduced combined rate of first and subsequent non-fatal MI, stroke, cardiovascular death, coronary revascularization, and hospitalizations of unstable angina and had the reduction of 25 to 30% in these primary endpoints.
The REDUCE-IT EPA analysis sought to assess the association of EPA blood levels in these above outcomes. Initial EPA levels were obtained prior to randomization. Icosapent 4 grams was compared to placebo. And results in EPA levels were noted, and were noted to increase by 386% in the treatment group. What did the researchers find? They found that on treatment, the higher EPA blood levels, the lower the rates of different cardiovascular events, death, and total mortality.
Indeed, the highest on treatment EPA levels experienced a significant reduction in hospitalization for new heart failure, sudden cardiac death, and cardiac arrest. So what's my take? I think it's really a very important study. The reduction in cardiovascular events and deaths among patients with cardiovascular disease or high-risk diabetes or other risk factors, who also had elevated cholesterol, they noted that taking 4 grams of a Icosapent daily was associated with higher levels of EPA and a significant decrease in cardiac events.
This observed benefit I believe allows us to embark on a new era in cardiovascular therapies. Thank you for joining me and see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw Hill. Subscribers to Access Cardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.
